TABLE 1

Latin American Thoracic Society (ALAT) Severe Asthma Guidelines questions

1) What is the definition of severe asthma?
2) What criteria are used to diagnose uncontrolled asthma?
3) What criteria are used to diagnose difficult-to-treat asthma?
4) What are the risk factors identified and associated with the development of severe asthma?
5) What are the phenotypes of severe asthma?
6) What are the predictive biomarkers for therapy response of patients with severe asthma?
7) What is the indication for the on-demand use of the combined therapy of an ICS and formoterol associated with maintenance treatment with an ICS and a LABA in patients with severe asthma?
8) Is there any additional benefit in adding theophylline in patients with severe asthma?
9) Is there any additional benefit in adding antileukotrienes in patients with severe asthma?
10) Is there any additional benefit when adding a long-acting anticholinergic drug (tiotropium) to ICS and LABA treatment in patients with severe asthma?
11) What is the efficacy and safety of anti-IgE monoclonal antibodies in the treatment of severe asthma in children and adults?
12) What is the efficacy and safety of anti-IL-5 monoclonal antibodies in the treatment of severe asthma in children and adults?
13) What is the efficacy and safety of anti-IL-5 receptor monoclonal antibodies in the treatment of severe asthma in children and adults?
14) What is the efficacy and safety of methotrexate in the treatment of severe asthma in children and adults?
15) What is the efficacy and safety of anti-IL-4 and IL-13 monoclonal antibodies in the treatment of severe asthma in children and adults?
16) What is the efficacy and safety of macrolides in the treatment of severe asthma in children and adults?
17) What is the efficacy and safety of bronchial thermoplasty in the treatment of severe asthma in children and adults?

ICS: inhaled corticosteroid; LABA: long-acting bronchodilator; IL: interleukin.